Genomic Health (GHDX) 26.51 $GHDX
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
10.6% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Thu Mar 27, 10:04AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 10.60% as of today's recent price of $27.00.
Genomic Health Unveils Oncotype DX Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:15PM CDT
Genomic Health presents results from multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
PR Newswire - Wed Mar 19, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX(R) in Europe
PR Newswire Europe - Wed Mar 19, 3:01AM CDT
-- Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Concise Analysis of the International Cancer Test Market
M2 - Thu Feb 27, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbhbjn/cancer_test) has announced the addition of the "Concise Analysis of the International Cancer Test Market" report to their offering. Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings. Accordingly, global expansion of cancer marker technologies may be fueled by an increased marketing of new diagnostic tests to physicians. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. The anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The global cancer test market is expected to be more than US$ 14 Billion by 2018. This study provides a comprehensive assessment of the fast-evolving, high-growth of Cancer Test market segment. This page report with 52 Figures and 57 Tables studies the Cancer Test Platform of 20 Companies. This report is broadly divided into 8 chapters. Key Topics Covered: Table of Contents 1. Executive Summary 2. Global - Cancer Testing Market and New Cases 3. Global - Cancer Testing Market Share 4. Global - Segment Wise Cancer Testing Market 5. Global - Organ Specific Cancer Testing Market 6. Cancer Diagnostics- Companies Novel Test Platforms & Pipeline Analysis (20 Companies Analysis) Companies Mentioned: - Abbott - BD Diagnostics - Beckman Coulter - BioCurex - Cepheid - CytoCore - DiagnoCure - Gen-Probe - Genomic Health - Myriad Genetics - Panacea Pharmaceuticals - QIAGEN Marseille (Earlier Ipsogen) - Qiagen - Radient Pharmaceuticals - Roche - Siemens Heathcare Diagnostics - TrovageneInc. - Ventana Medical Systems - Vermillion - bioMerieux For more information visit http://www.researchandmarkets.com/research/lb...ancer_test
What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:45AM CST
Genomic Health sees significant price decline in the past month along with falling earnings estimates
Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options
at The Street - Tue Feb 11, 10:24AM CST
Investors considering a purchase of Genomic Health stock, but tentative about paying the going market price of $27.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Genomic Health Down 13.6% Since SmarTrend Downtrend Call (GHDX)
Comtex SmarTrend(R) - Thu Apr 03, 10:02AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 13.61% as of today's recent price of $26.09.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
10.6% Return Seen to Date on SmarTrend Genomic Health Call (GHDX)
Comtex SmarTrend(R) - Thu Mar 27, 10:04AM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 2 months, Genomic Health has returned 10.60% as of today's recent price of $27.00.
Genomic Health Unveils Oncotype DX Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:15PM CDT
Genomic Health presents results from multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
PR Newswire - Wed Mar 19, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.
Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX(R) in Europe
PR Newswire Europe - Wed Mar 19, 3:01AM CDT
-- Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX
Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating
M2 - Tue Mar 18, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brn9sx/global_imaging) has announced the addition of the "Global Imaging Biomarkers Market 2014-2018 with Abbott, Agilent, Affymetrix, Siemens, Bio-Rad & F. Hoffmann La Roche Dominating" report to their offering. The use of imaging biomarkers in the field of drug discovery has increased considerably over the past few years. The increase in the demand for imaging biomarkers is primarily because of their ability to be used in target discovery and validation, identification of disease mechanisms, toxicity profiling, and proof-of-concept studies. The Global Imaging Biomarkers market has been witnessing an increase in the number of strategic alliances being formed among organizations. Mergers and acquisitions help organizations grow rapidly, expand their business processes, and gain more market share. The introduction of innovative technologies by small and mid-sized companies is prompting major pharmaceutical and biotechnology companies to form strategic alliances with these smaller companies to identify various imaging biomarkers. The increase in strategic alliances is resulting in an increase in the application base for imaging biomarkers in drug discovery and diagnosis domains. For instance, in 2012, Genomic Health Inc. and OncoMed Pharmaceuticals announced a strategic alliance for Biomarker Research and Discovery using the Next-generation Sequencing process. Further, the report states that one of the main challenges hindering the growth of this market is the presence of poor regulatory and reimbursements systems. The current regulatory and reimbursement systems present in various countries are not well-suited for imaging biomarker-based diagnostics. The development of novel and useful imaging biomarkers is also an expensive and time-consuming process. The key vendors dominating this market space are: - Abbott Laboratories - Agilent Technologies Inc. - Affymetrix Inc. - Bio-Rad Laboratories Inc. - F. Hoffmann La Roche Ltd. - Gen-Probe Inc. - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Trends and their Impact 15. Vendor Landscape 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/br...al_imaging
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018
M2 - Tue Mar 11, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9dp8rj/cancertumor) has announced the addition of the "Concise Analysis of the International Cancer/Tumor Profiling Market - Forecasts to 2018" report to their offering. The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment. The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Tumor Profiling Technology Landscape 4 Tumor Profiling Research Portfolio 5 Value Chain Analysis 6 Market Landscape Analysis 7 Technology Adoption And Development Potential, By Geography 8 Technology Investment Analysis 9 Competitive Landscape Analysis 10 Patent Analysis 11 Analyst Insights And Recommendations 12 Company Profiles Companies Mentioned: - Agendia Nv - Biotheranostics - Boreal Genomics, Inc - Caris Life Sciences - Genomic Health, Inc - Illumina, Inc - Life Technologies Corporation - Nanostring Technologies - Neogenomics Laboratories - Oncopath Laboratory - Oxford Gene Technology Ltd - Precision Therapeutics, Inc - Proteome Sciences Plc - Rational Therapeutics - Ribomed Biotechnologies For more information visit http://www.researchandmarkets.com/research/9d...ancertumor
Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year
PRWeb - Thu Mar 06, 8:11AM CST
The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to be held in San Francisco, CA on April 16-17, 2014.
Downtrend Call Working As Genomic Health Stock Falls 13.7% (GHDX)
Comtex SmarTrend(R) - Mon Mar 03, 10:59AM CST
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 27th, 2014 at $30.20. In approximately 1 month, Genomic Health has returned 13.68% as of today's recent price of $26.07.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Concise Analysis of the International Cancer Test Market
M2 - Thu Feb 27, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbhbjn/cancer_test) has announced the addition of the "Concise Analysis of the International Cancer Test Market" report to their offering. Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings. Accordingly, global expansion of cancer marker technologies may be fueled by an increased marketing of new diagnostic tests to physicians. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. The anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The global cancer test market is expected to be more than US$ 14 Billion by 2018. This study provides a comprehensive assessment of the fast-evolving, high-growth of Cancer Test market segment. This page report with 52 Figures and 57 Tables studies the Cancer Test Platform of 20 Companies. This report is broadly divided into 8 chapters. Key Topics Covered: Table of Contents 1. Executive Summary 2. Global - Cancer Testing Market and New Cases 3. Global - Cancer Testing Market Share 4. Global - Segment Wise Cancer Testing Market 5. Global - Organ Specific Cancer Testing Market 6. Cancer Diagnostics- Companies Novel Test Platforms & Pipeline Analysis (20 Companies Analysis) Companies Mentioned: - Abbott - BD Diagnostics - Beckman Coulter - BioCurex - Cepheid - CytoCore - DiagnoCure - Gen-Probe - Genomic Health - Myriad Genetics - Panacea Pharmaceuticals - QIAGEN Marseille (Earlier Ipsogen) - Qiagen - Radient Pharmaceuticals - Roche - Siemens Heathcare Diagnostics - TrovageneInc. - Ventana Medical Systems - Vermillion - bioMerieux For more information visit http://www.researchandmarkets.com/research/lb...ancer_test
What Makes Genomic Health (GHDX) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:45AM CST
Genomic Health sees significant price decline in the past month along with falling earnings estimates
Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options
at The Street - Tue Feb 11, 10:24AM CST
Investors considering a purchase of Genomic Health stock, but tentative about paying the going market price of $27.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
